Conservatives block committee shift, prompting minister-ordered audit of $300M PrescribeIT program failure
By
Tessie Sanci
Summary
Conservative MPs on the House Health Committee blocked Liberal attempts to move on from investigating Canada Health Infoway's terminated PrescribeIT program, a federally-funded e-prescribing system that cost $300 million. After a month of Conservative stonewalling, the minister ordered an audit and review of the program. Conservative health critic Dan Mazier argues the money has effectively been wasted.
Source

Key quotes
· 2 pulled$300-million has gone into nowhere.
Grit Health Committee members have been 'stonewalling' to prevent further study
You might also wanna read
Senators Investigate Pharmaceutical Companies' Direct-to-Consumer Telehealth Platforms for Steering Patients to High-Cost Drugs
U.S. senators are investigating direct-to-consumer (DTC) telehealth platforms operated by pharmaceutical companies like Eli Lilly and Pfizer
arstechnica.com·5mo ago
Canada's Bill C-22: A Poorly Designed Lawful Access Bill Being Rushed Through Committee
The article is a critical analysis of Canada's Bill C-22, a government lawful access bill. It argues that the bill is poorly designed, lacks
Federal Liberals shut down debate over proposed probe into B.C. condo buyout plan
Canadian Government Data Shows 23,746 Patients Died on Medical Waitlists in Past Year
Government data obtained through Freedom of Information requests reveals that 23,746 patients died on medical waitlists in Canada during the
secondstreet.org·6mo agoOpen-Source Analysis Identifies $98.6 Billion in Fixable US Healthcare Waste
This article presents an open-source investigative data journalism project that quantifies fixable waste in the US healthcare system. The an
Canada's Bill C-22 would mandate messaging app backdoors and one-year data retention
Bill C-22 in Canada would mandate that all messaging apps build government backdoors and retain user activity data for one year, effectively

Comments
Sign in to join the conversation.
No comments yet. Be the first.